
AbCellera Biologics Net Debt | ABCL
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt AbCellera Biologics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.7 M | -91 M | -55.9 M | -304 M | -461 M | -592 M | -3.72 M | -7 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 14.7 M | -592 M | -188 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Фармсинтез
LIFE
|
612 M | - | - | - | ||
|
AbbVie
ABBV
|
59.5 B | $ 257.12 | 0.86 % | $ 455 B | ||
|
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M | ||
|
Amryt Pharma plc
AMYT
|
-107 M | - | - | $ 621 M | ||
|
Evelo Biosciences
EVLO
|
-2.07 M | - | -14.46 % | $ 27.9 M | ||
|
ASLAN Pharmaceuticals Limited
ASLN
|
-13.8 M | - | -14.27 % | $ 1.7 M | ||
|
Acorda Therapeutics
ACOR
|
131 M | - | -24.86 % | $ 820 K | ||
|
Adaptimmune Therapeutics plc
ADAP
|
-36.2 M | - | -15.15 % | $ 60.3 M | ||
|
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | ||
|
Abeona Therapeutics
ABEO
|
-69.8 M | $ 5.42 | 0.18 % | $ 287 M | ||
|
iTeos Therapeutics
ITOS
|
-137 M | - | - | $ 411 M | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
-1.97 M | $ 4.63 | 21.05 % | $ 20 M | ||
|
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
-236 M | - | -0.23 % | $ 916 M | ||
|
BioXcel Therapeutics
BTAI
|
56.3 M | $ 0.07 | 9.81 % | $ 855 K | ||
|
Allakos
ALLK
|
-25 M | - | - | $ 28.6 M | ||
|
Cyclerion Therapeutics
CYCN
|
-51.1 M | $ 23.52 | 458.67 % | $ 98.9 M | ||
|
Lexicon Pharmaceuticals
LXRX
|
16.7 M | $ 2.0 | 0.3 % | $ 726 M | ||
|
Allena Pharmaceuticals
ALNA
|
-29.5 M | - | 3.16 % | $ 1.9 M | ||
|
Alpine Immune Sciences
ALPN
|
-34 M | - | - | $ 2.17 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
-35 M | $ 5.12 | 0.1 % | $ 981 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-12 M | - | -11.43 % | $ 502 K | ||
|
NextCure
NXTC
|
-20.8 M | $ 7.0 | 0.55 % | $ 19.9 M | ||
|
Aridis Pharmaceuticals
ARDS
|
-3.05 M | - | 17.91 % | $ 11.1 M | ||
|
Nanobiotix S.A.
NBTX
|
-80 M | $ 37.01 | 0.27 % | $ 1.77 T | ||
|
ACADIA Pharmaceuticals
ACAD
|
-126 M | $ 27.83 | 0.32 % | $ 4.69 B | ||
|
Axcella Health
AXLA
|
1.5 M | - | -16.42 % | $ 249 M | ||
|
SQZ Biotechnologies Company
SQZ
|
-36.2 M | - | 57.95 % | $ 12.8 M | ||
|
Atreca
BCEL
|
33.1 M | - | -11.76 % | $ 5.79 M | ||
|
Berkeley Lights
BLI
|
-60.5 M | - | -7.31 % | $ 87 M | ||
|
Bellerophon Therapeutics
BLPH
|
-23.8 M | - | -74.18 % | $ 955 K | ||
|
Achieve Life Sciences
ACHV
|
-9.68 M | $ 7.06 | 0.41 % | $ 308 M | ||
|
Baudax Bio
BXRX
|
1.86 M | - | 0.59 % | $ 63 K | ||
|
Calithera Biosciences
CALA
|
-23.8 M | - | -10.95 % | $ 876 K | ||
|
CymaBay Therapeutics
CBAY
|
-206 M | - | - | $ 3.45 B | ||
|
Codiak BioSciences
CDAK
|
-39.4 M | - | -55.98 % | $ 2.15 M | ||
|
ChemoCentryx
CCXI
|
-42.5 M | - | - | $ 3.74 B | ||
|
Avid Bioservices
CDMO
|
17.5 M | - | - | $ 789 M | ||
|
AC Immune SA
ACIU
|
-22.3 M | $ 2.76 | 2.6 % | $ 278 M | ||
|
Cerevel Therapeutics Holdings
CERE
|
-33.6 M | - | - | $ 7.29 B | ||
|
Aclaris Therapeutics
ACRS
|
-17.8 M | $ 5.32 | 1.27 % | $ 652 M | ||
|
Checkpoint Therapeutics
CKPT
|
-40.8 M | - | - | $ 169 M | ||
|
Adagene
ADAG
|
-73.3 M | $ 3.4 | 2.72 % | $ 201 M | ||
|
ADC Therapeutics SA
ADCT
|
-260 M | $ 1.07 | 0.45 % | $ 136 M | ||
|
Adial Pharmaceuticals
ADIL
|
-3.85 M | $ 4.9 | 0.08 % | $ 3.28 M | ||
|
ADMA Biologics
ADMA
|
-17.2 M | $ 9.23 | 0.16 % | $ 2.2 B | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
65 M | $ 24.2 | 0.08 % | $ 3.67 B | ||
|
Agenus
AGEN
|
-7.52 M | $ 6.94 | 0.73 % | $ 206 M | ||
|
Agios Pharmaceuticals
AGIO
|
-48.9 M | $ 33.6 | 0.16 % | $ 1.95 B |